Cancer treatments advance across multiple fronts with CDK4/6 and RET inhibitors showing promise, while surgical de-escalation strategies improve outcomes in breast cancer and brain metastases management.

Abemaciclib, a CDK4/6 inhibitor, extended progression-free survival more than sixfold in a phase 3 trial for patients with dedifferentiated liposarcoma, offering a significant therapeutic advance for this advanced soft tissue cancer.

Selpercatinib markedly improved event-free survival versus placebo in the first phase 3 trial of a RET inhibitor as adjuvant therapy for early-stage RET fusion-positive non-small cell lung cancer (NSCLC).

The largest randomized trial of its kind found that breast cancer patients who skipped completion axillary lymph node dissection achieved noninferior survival with better arm morbidity outcomes, supporting surgical de-escalation approaches.

Tafasitamab combined with lenalidomide is likely to gain approval with R-CHOP for frontline diffuse large B-cell lymphoma (DLBCL), though emerging bispecific antibodies may change the therapeutic landscape.

GammaTile, a tile-based radiation system, showed potential to improve outcomes over standard stereotactic radiotherapy following resection of large brain metastases, though striking overall survival benefits in a phase 3 trial warrant further scrutiny.

Primary care clinicians identified key barriers to effective lipid management and discussed practical strategies to improve cholesterol control in routine clinical practice.

Traffic pollution exposure has been linked to increased risk of chronic rhinosinusitis, with different pollutants potentially requiring targeted treatment approaches in the future.

An oncologist's shift in perspective after learning a patient's story demonstrates the importance of addressing psychological burden and self-blame in cancer treatment consultations.